CN104983701A - 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 - Google Patents

优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 Download PDF

Info

Publication number
CN104983701A
CN104983701A CN201510421108.2A CN201510421108A CN104983701A CN 104983701 A CN104983701 A CN 104983701A CN 201510421108 A CN201510421108 A CN 201510421108A CN 104983701 A CN104983701 A CN 104983701A
Authority
CN
China
Prior art keywords
posaconazole
composition
hpmc
pharmaceutical composition
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510421108.2A
Other languages
English (en)
Chinese (zh)
Inventor
L.Y.方
D.哈里斯
G.克里什娜
A.E.小莫顿
R.C.普雷斯蒂皮诺
M.施泰因曼
J.万
H.A.瓦斯金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41199703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104983701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN104983701A publication Critical patent/CN104983701A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201510421108.2A 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物 Pending CN104983701A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4517708P 2008-04-15 2008-04-15
US61/045177 2008-04-15
US16648709P 2009-04-03 2009-04-03
US61/166487 2009-04-03
CN2009801224878A CN102065842A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2009801224878A Division CN102065842A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Publications (1)

Publication Number Publication Date
CN104983701A true CN104983701A (zh) 2015-10-21

Family

ID=41199703

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2009801224878A Pending CN102065842A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
CN201510421108.2A Pending CN104983701A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2009801224878A Pending CN102065842A (zh) 2008-04-15 2009-04-15 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物

Country Status (19)

Country Link
US (2) US20110123627A1 (enExample)
EP (1) EP2285351A2 (enExample)
JP (3) JP2011516612A (enExample)
KR (1) KR20110004852A (enExample)
CN (2) CN102065842A (enExample)
AR (1) AR072858A1 (enExample)
AU (1) AU2009236289B2 (enExample)
BR (1) BRPI0910627A2 (enExample)
CA (1) CA2720849A1 (enExample)
CL (1) CL2009000902A1 (enExample)
CO (1) CO6311066A2 (enExample)
MX (1) MX2010011295A (enExample)
NZ (1) NZ588460A (enExample)
PE (1) PE20091778A1 (enExample)
PH (1) PH12015500492A1 (enExample)
SG (1) SG10201403986UA (enExample)
TW (1) TWI388324B (enExample)
WO (1) WO2009129300A2 (enExample)
ZA (1) ZA201007370B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EP2540318B1 (en) * 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
KR102228157B1 (ko) * 2013-06-03 2021-03-17 신에쓰 가가꾸 고교 가부시끼가이샤 가열 용융 압출용 조성물 및 이것을 사용한 가열 용융 압출 성형물의 제조 방법
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104510707A (zh) * 2013-09-26 2015-04-15 博瑞生物医药技术(苏州)有限公司 一种泊沙康唑固体分散体及其制备方法
CN104546667A (zh) * 2013-10-22 2015-04-29 博瑞生物医药技术(苏州)有限公司 含泊沙康唑的固体分散体及其制备方法
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
CN112022818A (zh) 2014-02-05 2020-12-04 默沙东公司 Cgrp-活性化合物的片剂制剂
CN110179801B (zh) * 2014-04-11 2021-08-06 上海宣泰医药科技股份有限公司 泊沙康唑药物组合物及其制备方法和药物制剂
WO2017025292A1 (en) 2015-08-08 2017-02-16 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant formulation containing posaconazole
EP4424308A3 (en) 2016-02-26 2024-12-04 Alfred E. Tiefenbacher (GmbH & Co. KG) Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
CN106265526A (zh) * 2016-09-22 2017-01-04 山东大学 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
US20180282527A1 (en) 2017-03-30 2018-10-04 Shin-Etsu Chemical Co., Ltd. Injection molding composition containing hypromellose acetate succinate and method for producing same
WO2020159562A1 (en) * 2019-01-29 2020-08-06 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
WO2021205473A1 (en) * 2020-04-06 2021-10-14 Bendale Yogesh Structurally defined, better tolerated, orally adminstered, processed arsenolite, a process for its preparation, a pharmaceutical composition and uses thereof
WO2022034232A1 (en) 2020-08-13 2022-02-17 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Gastro-resistant high-strength formulation containing posaconazole
CN112697937A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片溶出度的分析方法
EP4091604B1 (en) 2021-11-25 2024-04-03 Alfred E. Tiefenbacher (GmbH & Co. KG) Granules containing posaconazole
US20240390363A1 (en) 2021-11-25 2024-11-28 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Granules containing posaconazole
CN114184721A (zh) * 2021-12-14 2022-03-15 江苏恒盛药业有限公司 泊沙康唑残留溶剂的检测方法
CN115721601A (zh) * 2022-11-23 2023-03-03 无锡福祈制药有限公司 一种泊沙康唑纳米晶口服固体药物组合物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
US5703079A (en) * 1993-12-21 1997-12-30 Schering Corporation Tetrahydrofuran antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
DE69726729T2 (de) * 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungizide mittel mit verbesserter bioverfügbarkeit
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
CA2396380C (en) * 1999-12-23 2015-04-21 David Hayes Improved pharmaceutical compositions for poorly soluble drugs
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
EP1372394A1 (en) * 2001-04-03 2004-01-02 Schering Corporation Antifungal composition with enhanced bioavailability
WO2003077827A1 (en) * 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
US20060062848A1 (en) * 2004-09-17 2006-03-23 Nektar Therapeutics Uk Limited Formulation comprising itraconazole
US20060275230A1 (en) * 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
BRPI0712130A2 (pt) * 2006-05-30 2012-01-17 Elan Pharma Int Ltd formulações de posaconazol em nanopartìculas
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas

Also Published As

Publication number Publication date
BRPI0910627A2 (pt) 2015-09-22
ZA201007370B (en) 2011-06-29
JP2016074698A (ja) 2016-05-12
KR20110004852A (ko) 2011-01-14
EP2285351A2 (en) 2011-02-23
WO2009129300A2 (en) 2009-10-22
JP2011516612A (ja) 2011-05-26
CL2009000902A1 (es) 2010-07-23
MX2010011295A (es) 2010-11-12
AU2009236289A1 (en) 2009-10-22
WO2009129300A3 (en) 2010-02-11
NZ588460A (en) 2012-07-27
PE20091778A1 (es) 2009-11-13
JP2014139230A (ja) 2014-07-31
AU2009236289B2 (en) 2014-08-21
CO6311066A2 (es) 2011-08-22
US20150150990A1 (en) 2015-06-04
TW200946121A (en) 2009-11-16
TWI388324B (zh) 2013-03-11
SG10201403986UA (en) 2014-10-30
US20110123627A1 (en) 2011-05-26
CA2720849A1 (en) 2009-10-22
CN102065842A (zh) 2011-05-18
PH12015500492A1 (en) 2017-04-10
AR072858A1 (es) 2010-09-29

Similar Documents

Publication Publication Date Title
CN104983701A (zh) 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
US20230248655A1 (en) Tablet formulation for cgrp active compounds
US5340589A (en) Low solubility drug-coated bead compositions
CN108785256B (zh) 一种固体分散体及其制备方法
EP2953615B1 (en) Solid dispersion comprising amorphous cilostazol
US20210128536A1 (en) Weakly basic drug and ionic polymer pharmaceutical formulations and methods of formation and administration thereof
CN113081970A (zh) 一种环孢素固体分散体及其片剂制备方法
EP3572069A1 (en) Increasing solubility and bioavailability of enzalutamide
AU2014265059A1 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
WO2024024938A1 (ja) デラマニド含有固体分散体
HK40090396A (zh) 包含环状膦酸酯化合物的药物组合物及其制备方法与用途
HK1218618B (en) Solid dispersion comprising amorphous cilostazol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151021